PRESENTATION
Q4 2022 — Results presentation
Q4 2022PDF · 40 pages4.4 MB
-- 1 of 40 -- 4th Quarter 2022 Earnings Call January 24, 2023 -- 2 of 40 -- Cautionary Note on Forward-looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm. 3 -- 3 of 40 -- Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Infectious Diseases PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS) Cardiovascular/ Metabolism/Other INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; cilta-cel licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc. Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Global Public Health Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C. Strategic Partnerships, Collaborations & Licensing Arrangements 4 During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: -- 4 of 40 -- 5 Agenda CEO Remarks Enterprise Highlights Sales Performance and Earnings Review Capital Allocation and Guidance Q&A 1 2 3 4 5 Joseph J. Wolk Executive Vice President, Chief Financial Officer Jessica Moore Vice President, Investor Relations Joaquin Duato Chairman of the Board and Chief Executive Officer -- 5 of 40 -- Joaquin Duato Chairman of the Board and Chief Executive Officer -- 6 of 40 -- 7 -- 7 of 40 -- -- 8 of 40 -- 9 -- 9 of 40 -- -- 10 of 40 -- -- 11 of 40 -- 12 -- 12 of 40 -- -- 13 of 40 -- 14 -- 14 of 40 -- 15 -- 15 of 40 -- 16 -- 16 of 40 -- Jessica Moore Vice President, Investor Relations -- 17 of 40 -- Regional Sales Results Q4 2022 Q4 2021 % CHANGE Reported Operational1 U.S. $12.5 $12.2 2.9% 2.9% Europe 5.8 6.9 (16.0) (6.3) Western Hemisphere (ex U.S.) 1.5 1.5 5.9 11.8 Asia-Pacific, Africa 3.8 4.3 (10.0) 3.1 International 11.2 12.6 (11.5) (1.1) Worldwide (WW) $23.7 $24.8 (4.4)% 0.9% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 4th Quarter 2022 Sales Dollars in Billions 18 -- 18 of 40 -- 10.3%; 15.5% 1 Q4 2022 Q4 2021 $2.35 $2.13 4th Quarter 2022 Financial Highlights Dollars in Billions, except EPS Reported %; Operational % 1 19 Sales Adjusted Earnings 2 Adjusted EPS2 (4.4)%; 0.9% 1 GAAP Earnings (25.7)% $3.5 $4.7 9.5% Q4 2022 Q4 2021 GAAP EPS (24.9)% $1.33 $1.77 Q4 2022 Q4 2022 Q4 2021 Q4 2021 Q4 2022 Q4 2021 $6.2 $5.7 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website $23.7 $24.8 -- 19 of 40 -- Regional Sales Results 2022 2021 % CHANGE Reported Operational1 U.S. $48.6 $47.2 3.0% 3.0% Europe 23.4 23.6 (0.6) 11.0 Western Hemisphere (ex U.S.) 6.1 5.8 6.5 10.2 Asia-Pacific, Africa 16.8 17.3 (2.8) 6.2 International 46.4 46.6 (0.6) 9.1 Worldwide (WW) $94.9 $93.8 1.3% 6.1% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding Full Year 2022 Sales Dollars in Billions 20 -- 20 of 40 -- 3.6%; 9.2% 1 2022 2021 $10.15 $9.80 Full Year 2022 Financial Highlights Dollars in Billions, except EPS Reported %; Operational % 1 21 Sales Adjusted Earnings 2 Adjusted EPS2 1.3%; 6.1% 1 $94.9 $93.8 GAAP Earnings (14.1)% $17.9 $20.9 3.2% 2022 2021 GAAP EPS (13.8)% $6.73 $7.81 2022 2022 2021 2021 2022 2021 $27.0 $26.2 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website -- 21 of 40 -- OTC $1,569 Skin Health/Beauty $1,088 Oral Care $370 Baby Care $356 Women's Health $220 Wound Care/Other $163 $3,767 1.0%, 6.4% WW Sales $MM ■ Reported Growth ■ Operational Growth 1 Consumer Health Highlights – 4th Quarter 2022 Operational growth 1 driven by OTC and U.S. Skin Health / Beauty 22 Key Drivers of Operational Performance1,3 OTC3 • Growth driven by price actions primarily in the U.S., increased Cough/Cold/Flu adult and pediatric incidences, and category recovery, partially offset by supply constraints Skin Health/ Beauty • Growth driven by price actions, lapping prior year higher-level of supply constraints, and NEUTROGENA strength in club and e-commerce channels, partially offset by U.S. portfolio simplification, negative impacts of COVID-19 in China, and suspension of personal care sales in Russia Oral Care • Decline driven by category decline, competitive pressures in EMEA and China, and negative impacts of COVID-19 in China, partially offset by price actions Baby Care • Decline driven by weakness in India, negative impacts of COVID-19 in China, and suspension of personal care sales in Russia, partially offset by price actions Women’s Health • Growth driven by price actions and continued strong performance in India Wound Care/Other • Growth driven by price actions and supply recovery Adjusted Operational Sales2,3: WW 6.4%, U.S. 11.0%, Int’l 3.2% Reported 3: WW 1.0%, U.S. 10.9%, Int’l (5.8)% Operational1,3: WW 6.4%, U.S. 10.9%, Int’l 3.2% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website 3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding 8.6%, 13.7% (5.5)%, 4.6% (0.5)%, 3.1% (10.6)%, (5.0)% (8.4)%, (3.7)% 0.4%, 5.4% 3 -- 22 of 40 -- Key Drivers of Operational Performance1,3 Immunology • STELARA increase driven by market and share growth in both CD and UC, as well as a favorable PPA, partially offset by unfavorable patient mix, increased rebates, timing of shipments in ASPAC, and austerity measures in Europe • Strength in TREMFYA due to share gains in both PsO and PsA and market growth, partially offset by an unfavorable PPA, patient mix, and rebates • REMICADE decline due to biosimilar competition Infectious Diseases 3 • Decline driven by the COVID-19 Vaccine and increased OUS competition for PREZISTA/PREZCOBIX/REZOLSTA Neuroscience 3 • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA driven by new patient starts and persistency, and launch of INVEGA HAFYERA, partially offset by unfavorable patient mix, PPAs, and the loss of exclusivity in EU Oncology • DARZALEX increase driven by share gains in all regions, continued strong market growth, and uptake of the subcutaneous formulation • Continued strong share gains and market growth for ERLEADA • Growth partially offset by ZYTIGA loss of exclusivity in EU • IMBRUVICA decline due to global competitive pressures and a suppressed CLL market, but maintains its market leadership position Cardiovascular/ Metabolism/ Other (CVM/Other)3 • XARELTO increase due to volume growth and share gains, partially offset by patient mix and rebating • INVOKANA/INVOKAMET decline due to continued competitive pressures and increased utilization of government channels Pulmonary Hypertension (PH) • Increase driven by strong market growth and share gains from UPTRAVI and OPSUMIT, despite COVID-19 related pressures • Continued declines in Other Pulmonary Hypertension Adjusted Operational Sales2,3: WW (2.3)%, U.S. (0.4)%, Int’l (4.4)% Immunology $4,118 Infectious Diseases $1,540 Neuroscience $1,737 Oncology $3,927 CVM/Other $971 PH $870 $13,163 (7.4)%, (2.5)% WW Sales $MM ■ Reported Growth ■ Operational Growth 1 Pharmaceutical Highlights – 4th Quarter 2022 23 Reported 3: WW (7.4)%, U.S. (0.6)%, Int’l (14.9)% Operational1,3: WW (2.5)%, U.S. (0.6)%, Int’l (4.5)% (4.2)%, (2.4)% 2.3%, 6.9% 3.9%, 10.9% (2.8)%, 2.4% (36.6)%, (31.4)% (5.4)%, (1.8)% Excluding COVID-19 Vaccine, solid operational growth 1 driven by key brands 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website 3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding 3 3 3 -- 23 of 40 -- Orthopaedics $2,148 Surgery $2,384 Vision $1,145 Interventional Solutions $1,098 $6,776 (1.2)%, 4.9% WW Sales $MM ■ Reported Growth ■ Operational Growth 1 MedTech Highlights – 4th Quarter 2022 Operational growth 1 driven by market recovery and innovation partially offset by impacts in China 24 Reported: WW (1.2)%, U.S. 7.1%, Int’l (8.6)% Operational1: WW 4.9%, U.S. 7.1%, Int’l 2.9% Key Drivers of Operational Performance1 Interventional Solutions • Electrophysiology: Double digit increase driven by market growth, new product performance (OCTARAY, QDOT and VIZIGO), and commercial execution, partially offset by COVID-19 related procedure disruption in China • Abiomed: Includes sales as of December 22, 2022 Orthopaedics • Hips: Growth (~ +10% U.S. / ~ +6% WW) reflects continued procedure recovery and strength across the portfolio (ACTIS Stem and PINNACLE Dual Mobility with pull through enabled by KINCISE & VELYS Hip Navigation) partially offset by impacts of volume-based procurement and COVID-19 related procedure disruption in China • Trauma: Growth primarily driven by uptake of recently launched products (Advanced Nailing Systems, VA Clavicle) partially offset by softer procedure volumes in the U.S. and impacts of volume-based procurement and COVID-19 related procedure disruption in China • Knees: Growth (~ +12% U.S. / ~ +8% WW) driven primarily by procedure recovery, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution, partially offset by impacts of volume-based procurement and COVID-19 related procedure disruption in China and timing of OUS tenders • Spine, Sports & Other: Growth reflects market recovery and benefit from new products (VELYS Digital Solutions, INHANCE, SYMPHONY), partially offset by impacts of volume-based procurement and COVID-19 related procedure disruption in China and competitive pressures in Spine • Spine: WW: ~ -6%, U.S.: ~ +2%, OUS ~ -17% Surgery • Advanced: • Endocutters: ~ -1% Primarily due to impacts of volume-based procurement and COVID-19 related procedure disruption in China as well as stocking reductions and competitive pressures predominately in the U.S. Decline was partially offset by market recovery and strength of new products OUS and a benefit from a reclass from General Surgery (~+110 bps). • Biosurgery: ~ +2% Reflects benefits from new products (SURGIFLO, SURGICEL Powder and VISTASEAL) partially offset by strong U.S. market demand in the prior year for infection prevention products and COVID-19 related procedure disruption in China • Energy: ~ Flat driven by strength of new products (ENSEAL X1, HD1000i) coupled with competitive supply challenges, offset by impacts of volume-based procurement and COVID-19 related procedure disruption in China • General: Growth driven primarily by market recovery coupled with technology penetration (Barbed & PLUS Sutures) Vision • Contact Lenses/Other: Growth driven by strong performance in the ACUVUE OASYS 1-Day family (including recent launches of OASYS MAX 1-day and OASYS Multifocal), price actions, and effective commercial execution, partially offset by supply challenges • Surgical: Decline reflects comparisons to strong prior year Refractive market and supply challenges, partially offset by strong demand for TECNIS portfolio (including recently launched products TECNIS Eyhance and TECNIS Synergy) Adjusted Operational Sales 2: WW 4.4%, U.S. 5.9%, Int’l 3.0% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding; The MedTech segment was previously referred to as the Medical Devices segment 7.8%, 15.1% (2.2)%, 4.8% (0.4)%, 4.0% (5.1)%, 1.4% -- 24 of 40 -- 2022 2021 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $23,706 100.0 $24,804 100.0 (4.4) Cost of products sold 7,765 32.8 7,955 32.1 (2.4) Gross Profit 15,941 67.2 16,849 67.9 (5.4) Selling, marketing and administrative expenses 6,512 27.4 7,154 28.9 (9.0) Research and development expense 3,841 16.2 4,720 19.0 (18.6) In-process research and development 173 0.7 0 0.0 Interest (income) expense, net (77) (0.3) 47 0.2 Other (income) expense, net 1,207 5.1 9 0.0 Restructuring 84 0.4 83 0.3 Earnings before provision for taxes on income 4,201 17.7 4,836 19.5 (13.1) Provision for taxes on income 681 2.9 100 0.4 581.0 Net Earnings $3,520 14.8 $4,736 19.1 (25.7) - Net earnings per share (Diluted) $1.33 $1.77 (24.9) Average shares outstanding (Diluted) 2,650.1 2,670.2 Effective tax rate 16.2% 2.1% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $7,418 31.3 $6,339 25.6 17.0 Net earnings $6,218 26.2 $5,678 22.9 9.5 Net earnings per share (Diluted) $2.35 $2.13 10.3 Effective tax rate 16.2% 10.4% Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 25 4 th Quarter 2022 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 25 of 40 -- 2022 2021 Adjusted Income Before Tax by Segment1 4 th Quarter 2022 26 Pharmaceutical MedTech Consumer Health Expenses Not Allocated to Segments Q4 2022 Q4 2021 Pharmaceutical 3 38.2% 33.9% MedTech 25.3% 18.1% Consumer Health 3 22.0% 18.6% Total 31.3% 25.6% % to Sales 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 1/24/2023 3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes Note: Values may not add due to rounding ($0.2) ($0.4) $6.3B $4.8 $1.2 $0.7 $7.4B $5.0 $1.7 $0.8 2 -- 26 of 40 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 27 of 40 -- Notable Announcements in 4th Quarter 2022 1 Pharmaceutical • Regulatory: – U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma – Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma • Data Release: – New TREMFYA (guselkumab) Data Shows an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis – Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio – Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension – New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life – New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population MedTech • Regulatory: – DePuy Synthes Receives FDA Clearance for TELIGEN System • Data Release: – CERENOVUS Reveals Positive Outcomes with Thrombectomy in Global Registry Studying Stroke-Inducing Blood Clots Enterprise – Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board – Johnson & Johnson Completes Acquisition of Abiomed 28 1 These developments and all other news releases are available on the company’s website at news releases or JNJ.com news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com -- 28 of 40 -- Capital Allocation Strategy Capital Allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases HIGHER PRIORITY LOWER PRIORITY Investment in M&A Dollars in Billions Q4 2022 Cash and Marketable Securities $24 Debt ($40) Net Debt ($16) Free Cash Flow1,2 ~$17 Full Year 2022: $14.6B invested in R&D $11.7B in dividends paid to shareholders Note: values may have been rounded 1 Non-GAAP measure; cash flow from operations less CAPEX 2 Estimated as of January 24, 2023. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings 3 Announced $5B share repurchase program on September 14, 2022 29 Note: values may have been rounded $2.5B in share repurchases; ~50% of the program completed 3 -- 29 of 40 -- 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: January 2023 = $1.08 6 Excludes COVID-19 Vaccine Note: Percentages may be rounded 30 2023 P&L Guidance January Comments Adjusted Operational Sales1,2,6 3.5% - 4.5% Midpoint of 4.0% Operational Sales2,6 $96.9B - $97.9B 4.5% – 5.5% Midpoint of $97.4B or 5.0% Estimated Reported Sales 3,6 $96.9B - $97.9B 4.5% – 5.5% No FX impact Adjusted Pre-Tax Operating Margin4,5 Approximately flat OPEX leverage offset by inflationary pressures Net Other Income4 $1.9 - $2.1 billion Favorable employee benefit-related items Net Interest Expense / (Income) $250 - $350 million Financing charges related to the Abiomed Acquisition Effective Tax Rate 4 15.5% - 16.5% Based on current tax laws and anticipated geographic mix Adjusted EPS (Operational) 2,4 $10.40 - $10.60 2.5% - 4.5% Midpoint of $10.50 or 3.5% Adjusted EPS (Reported) 3,4 $10.45 - $10.65 3.0% - 5.0% +$0.05 or +0.5% FX impact Midpoint of $10.55 or 4.0% -- 30 of 40 -- 2023 Sales Commentary • Anticipate first half operational sales growth lower than the second half driven by: o Ongoing procedure recovery o Q4 COVID-19 impacts in China continuing into 2023 o Ramp of new product launches Pharmaceutical MedTech 31 January Adjusted Operational Sales1,2,4 3.5% - 4.5% Operational Sales2,4 $96.9B - $97.9B 4.5% – 5.5% Estimated Reported Sales 3,4 $96.9B - $97.9B 4.5% – 5.5% 1 Non-GAAP measure; excludes acquisitions and divestitures 3 Euro Average Rate: January 2023 = $1.08 2 Non-GAAP measure; excludes the impact of translational currency 4 Excludes COVID-19 Vaccine Note: Percentages may be rounded • Anticipate first half operational sales growth lower than the second half driven by: o Impact from LOE products in Europe o Ramp of new product launches o Continued pricing pressures • Pharmaceutical: Above market growth driven by key brands and uptake of recently launched products partially offset by LOEs • MedTech: Competitive growth fueled by market recovery and uptake of recently launched products • Consumer Health: Growth in-line with the market and strategic pricing to offset inflationary pressures Adjusted Operational Sales Commentary by Segment Phasing Considerations by Segment -- 31 of 40 -- 32 Anticipated 2023 Milestones Driving Long-Term Value Creation Pharmaceutical Important launches, approvals and data readouts Consumer Health Expect to complete the separation MedTech Key pipeline program updates -- 32 of 40 -- Q&A Joseph J. Wolk Executive Vice President, Chief Financial Officer Jessica Moore Vice President, Investor Relations Chairman of the Board and Chief Executive Officer Joaquin Duato -- 33 of 40 -- -- 34 of 40 -- OTC $6,031 Skin Health/Beauty $4,352 Oral Care $1,505 Baby Care $1,461 Women's Health $904 Wound Care/Other $700 $14,953 (0.5)%, 3.6% WW Sales $MM ■ Reported Growth ■ Operational Growth 1 Consumer Health Highlights – Full Year 2022 Adjusted operational 2 growth driven by OTC 35 Key Drivers of Operational Performance1,3 OTC3 • Growth driven by increased Cough/Cold/Flu, adult and pediatric incidences, price actions primarily in the U.S., and increased consumption due in China due to COVID- 19, partially offset by supply constraints Skin Health/ Beauty • Decline driven by supply constraints in the U.S. partially offset by price actions and strong new product performance in ASPAC and LATAM Oral Care • Decline driven by portfolio simplification in the U.S., competitive pressures in EMEA and China, category decline and pricing pressures in EMEA, as well as suspension of personal care sales in Russia and negative COVID-19 impacts in China Baby Care • Decline driven by category deceleration and competitive pressures in the U.S., suspension of personal care sales in Russia, and weakness in India Women’s Health • Growth driven by lapping prior year supply constraints in EMEA, strength in India, and price actions in LATAM, partially offset by suspension of personal care sales in Russia Wound Care/Other • Decline driven by lapping strong prior year consumption, competitive pressure in the U.S., and decreased consumption in China Adjusted Operational Sales2,3: WW 3.9%, U.S. 1.5%, Int’l 5.8% Reported 3: WW (0.5)%, U.S. 1.3%, Int’l (1.9)% Operational1,3: WW 3.6%, U.S. 1.3%, Int’l 5.3% 7.2%, 11.2% (1.5)%, 7.0% (5.3)%, (3.8)% (6.7)%, (2.4)% (8.5)%, (4.7)% (4.2)%, (0.4)% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website 3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding 3 -- 35 of 40 -- 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website 3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding Key Drivers of Operational Performance1,3 Immunology • Growth driven by continued strong uptake of STELARA in CD and UC • Strength of TREMFYA in PsO and uptake in PsA • REMICADE decline due to biosimilar competition Infectious Diseases 3 • Growth driven by the contribution of the COVID-19 Vaccine • Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and PREZISTA OUS LOE Neuroscience 3 • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and persistency, and the launch of INVEGA HAFYERA Oncology • DARZALEX increase driven by continued strong market growth and share gains in all regions and uptake of the subcutaneous formulation • Continued strong global launch uptake of ERLEADA • IMBRUVICA decline primarily driven competitive pressures and market suppression • ZYTIGA decline due to loss of exclusivity in EU Cardiovascular/ Metabolism/ Other (CVM/Other)3 • Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition • INVOKANA/INVOKAMET decline due to continued share erosion Pulmonary Hypertension (PH) • Growth driven by sales of OPSUMIT and UPTRAVI due to continued share gains and market growth, despite COVID-19 pressures Adjusted Operational Sales2,3: WW 6.8%, U.S. 2.5%, Int’l 12.0% Immunology $16,935 Infectious Diseases $5,449 Neuroscience $6,893 Oncology $15,983 CVM/Other $3,887 PH $3,417 $52,563 1.7%, 6.7% WW Sales $MM ■ Reported Growth ■ Operational Growth 1 Pharmaceutical Highlights – Full Year 2022 36 Reported 3: WW 1.7%, U.S. 2.3%, Int’l 1.0% Operational1,3: WW 6.7%, U.S. 2.3%, Int’l 11.9% (5.6)%, (4.0)% (1.0)%, 3.0% 9.9%, 16.9% (1.4)%, 3.4% (6.5)%, 0.8% 1.1%, 4.8% 11 th consecutive year of above-market performance driven by double-digit growth in key products 3 3 3 -- 36 of 40 -- Orthopaedics $8,587 Surgery $9,690 Vision $4,849 Interventional Solutions $4,300 $27,427 1.4%, 6.2% WW Sales $MM ■ Reported Growth ■ Operational Growth 1 MedTech Highlights – Full Year 2022 Growth primarily driven by market recovery, commercial initiatives and innovation 37 Reported: WW 1.4%, U.S. 5.4%, Int’l (2.3)% Operational1: WW 6.2%, U.S. 5.4%, Int’l 6.9% Key Drivers of Operational Performance1 Interventional Solutions • Electrophysiology: Market recovery, success of new products (VIZIGO and CARTO V7), and commercial strategies continuing to enhance global leadership Orthopaedics • Hips: Growth reflects market recovery combined with continued strength of our portfolio including ACTIS Stem and pull through from enabling technologies – KINCISE & VELYS Hip Navigation, partially offset by volume-based procurement in China and OUS tender timing • Trauma: Growth reflects global market recovery and uptake of new products including Advanced Nailing Systems and VA Clavicle • Knees: Growth primarily driven by procedure recovery, strength of the ATTUNE portfolio, and pull through related to the VELYS Robotic assisted solution, partially offset by volume-based procurement in China and OUS tender timing • Spine, Sports & Other: Growth driven primarily by market recovery and benefit from new products (VELYS Digital Solutions, INHANCE, SYMPHONY), partially offset by competitive pressures in Spine and impacts of volume-based procurement • Spine: WW: ~ -4%, U.S.: ~ -5%, OUS: ~ -1% Surgery • Advanced: • Endocutters: ~ +3% Driven by market recovery, new products (ECHELON Staple Line Reinforcement), and a reclass from General Surgery offsetting competitive pressure in the U.S. • Biosurgery: ~ +5% Market recovery and success of newer products (VISTASEAL and SURGICEL POWDER), partially offset by strong market demand in the prior year for infection prevention products • Energy: ~ +3% Primarily due to market recovery, benefits from new products (ENSEAL & HARMONIC), and competitive supply challenges • General: Growth primarily driven by market recovery and continued strength of the Suture portfolio Vision • Contact Lenses/Other: Growth driven primarily by market recovery and benefits from new products (ACUVUE OASYS MAX and ACUVUE OASYS Multifocal) • Surgical: Growth primarily due to market recovery and benefits from uptake of recently launched products (TECNIS EYHANCE and TECNIS SYNERGY), partially offset by higher prior year U.S. Refractory market Adjusted Operational Sales2: WW 6.1%, U.S. 5.0%, Int’l 7.0% 8.3%, 13.7% 3.4%, 9.5% 0.0%, 3.7% (1.2)%, 3.8% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding; The MedTech segment was previously referred to as the Medical Devices segment -- 37 of 40 -- 2022 2021 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $94,943 100.0 $93,775 100.0 1.3 Cost of products sold 31,089 32.7 29,855 31.8 4.1 Gross Profit 63,854 67.3 63,920 68.2 (0.1) Selling, marketing and administrative expenses 24,765 26.1 24,659 26.3 0.4 Research and development expense 14,603 15.4 14,714 15.7 (0.8) In-process research and development 783 0.8 900 1.0 Interest (income) expense, net (214) (0.2) 130 0.1 Other (income) expense, net 1,871 2.0 489 0.5 Restructuring 321 0.3 252 0.3 Earnings before provision for taxes on income 21,725 22.9 22,776 24.3 (4.6) Provision for taxes on income 3,784 4.0 1,898 2.0 99.4 Net Earnings $17,941 18.9 $20,878 22.3 (14.1) - Net earnings per share (Diluted) $6.73 $7.81 (13.8) Average shares outstanding (Diluted) 2,663.9 2,674.0 Effective tax rate 17.4% 8.3% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $31,880 33.6 $30,464 32.5 4.6 Net earnings $27,038 28.5 $26,195 27.9 3.2 Net earnings per share (Diluted) $10.15 $9.80 3.6 Effective tax rate 15.2% 14.0% Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 38 Full Year 2022 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 38 of 40 -- Adjusted Income Before Tax by Segment1 Full Year 2022 39 Pharmaceutical MedTech Consumer Health Expenses Not Allocated to Segments FY 2022 FY 2021 Pharmaceutical 3 41.5% 40.4% MedTech 26.1% 25.7% Consumer Health 3 23.6% 24.5% Total 33.6% 32.5% % to Sales 2022 2021 ($0.6) ($1.1) $30.5B $20.9 $7.0 $3.7 $31.9B $21.8 $7.2 $3.5 2 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 1/24/2023 3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes -- 39 of 40 -- 40 -- 40 of 40 --